Business
-
UK-based Essential Pharma announced that it has acquired the rights to market Bayer’s Ventavis iloprost trometamol inhalation solution for the treatment of primary pulmonary hypertension in all markets except for the US and Russia. Essential… Read more . . .
-
Iliad Biotechnologies announced that it has raised $115 million in a Series B financing to support continued development of the company’s BPZE1 intranasal vaccine against pertussis (whooping cough). The company said that it intends to… Read more . . .
-
Israeli psychedelic drug developer Clearmind Medicine has signed an agreement with Polyrizon for development of an intranasal formulation of Clearmind’s 5‑methoxy‑2‑aminoindane (MEAI) based on Polyrizon’s intranasal hydrogel technology, the companies said. According to Clearmind, MEAI… Read more . . .
-
Milestone Pharmaceuticals’ Cardamyst etripamil nasal spray is now available in US pharmacies, and a national sales campaign is expected to begin within the next few weeks, the company said. The FDA approved Cardamyst for the… Read more . . .
-
US-based OINDP instrument and testing specialist Proveris Scientific has been acquired by Investindustrial, which describes itself as “one of Europe’s leading independent investment groups focused on taking majority or control positions, in quality leading mid-market companies.”… Read more . . .
-
Frazier Life Sciences has launched a new company called AirNexis Therapeutics, which will develop inhaled suspension and dry powder formulations of HSK39004, a dual PDE3/4 inhibitor for the treatment of COPD that it has licensed… Read more . . .
-
Kinaset Therapeutics announced that it has raised $103 million in a Series B financing, with proceeds to be used for development of its KN-002 frevecitinib DPI for the treatment of asthma. The financing was led… Read more . . .
-
Nocion Therapeutics said that it has raised an additional $23 million, expanding a Series B financing that raised $62 million in 2024 for development of the company’s taplucainium DPI for the treatment of chronic cough.… Read more . . .
-
Cipla has launched Afrezza inhaled dry powder insulin for the treatment of diabetes in adult patients in India, the company said. Cipla acquired the rights to market Afrezza in India from MannKind Corporation in 2018,… Read more . . .
-
More than a year after agreeing to merge, DPI developer Pulmatrix, and biopharm Cullgen have agreed to waive a no solicitation clause included in the November 2024 merger agreement. According to the announcement, the companies… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland